This Phase 3 study will evaluate the safety and tolerability of revaccination of the RSV vaccine and will assess the immune response following revaccination at approximately 1-, 2-, and 3-year intervals to inform the revaccination interval in immunocompromised individuals.
The study is looking for individuals ages 18 years and older who have an immunocompromising condition or take a medication that suppresses the immune system. It requires up to 5 in-clinic visits over 12 months.
Please use this link to sign up.
Sponsor(s)
Pfizer Inc.
Principal Investigator(s)
David Diemert, MD
Contact Phone Number
Request Information
